Acalabrutinib Efficacy and NCCN Recommendations for Small Lymphocytic Lymphoma

First‑Line Treatment in Treatment‑Naïve Patients

The NCCN (Category 2A) recommends acalabrutinib + obinutuzumab for treatment‑naïve SLL, achieving an overall response rate of 94 % (including 13 % complete responses) and a 2‑year progression‑free survival (PFS) of 93 %, markedly superior to chlorambucil + obinutuzumab (47 % PFS)【2】【3】.
Acalabrutinib monotherapy (Category 2A) yields an overall response rate of 85 % (all partial responses) with a 2‑year PFS of 87 % in the same ELEVATE‑TN cohort【2】【3】.
The PFS advantage of acalabrutinib‑based regimens is consistent across IGHV mutational status and other predefined subgroups【2】.
Grade ≥ 3 neutropenia occurs in ≈30 % of patients receiving acalabrutinib + obinutuzumab versus ≈10 % with acalabrutinib alone, informing toxicity‑guided selection【2】【3】.

The NCCN (Category 1) designates acalabrutinib as the preferred regimen for relapsed/refractory SLL, based on the ASCEND trial showing an overall response rate of 81 % and a 1‑year PFS of 88 %, compared with 68‑69 % for chemotherapy‑based regimens【1】.
In ASCEND, median PFS was not reached at a median follow‑up of 16 months (P < 0.0001 versus comparators)【1】.
Acalabrutinib was upgraded from Category 2A to Category 1 in NCCN guidelines after the ASCEND results【1】.
For patients intolerant to ibrutinib, acalabrutinib provides an overall response rate of 76 % and an estimated 2‑year PFS of 75 % after a median 19‑month follow‑up【1】.
Acalabrutinib is ineffective in CLL/SLL harboring BTK C481S mutations that confer resistance to prior ibrutinib therapy【1】.

In SLL with del(17p) or TP53 mutation, acalabrutinib achieves an overall response rate of 85 %, and the 18‑month PFS has not been reached, supporting its use as the optimal choice in this high‑risk subgroup【5】.
Del(17p) and TP53 mutations occur in approximately 9‑10 % and 11‑12 % of patients, respectively, yet acalabrutinib maintains PFS benefit across these cytogenetic subgroups【5】.

NCCN recommends continuous acalabrutinib therapy until disease progression for both treatment‑naïve and relapsed patients【2】【3】.
Five‑year follow‑up of the ELEVATE‑TN trial confirms sustained superiority of acalabrutinib‑based therapy, with a hazard ratio for PFS of 0.11 (95 % CI 0.07‑0.67, P < 0.0001) and for overall survival of 0.55 (95 % CI 0.30‑0.99) versus chlorambucil + obinutuzumab【4】.

NCCN advises preferring acalabrutinib over ibrutinib in patients with existing cardiovascular comorbidities, given its more favorable cardiac safety profile【4】.